139 related articles for article (PubMed ID: 36281718)
1. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
Krul IM; Boekel NB; Kramer I; Janus CPM; Krol ADG; Nijziel MR; Zijlstra JM; van der Maazen RWM; Roesink JM; Jacobse JN; Schaapveld M; Schmidt MK; Opstal-van Winden AWJ; Sonke GS; Russell NS; Aleman BMP; van Leeuwen FE
Cancer; 2022 Dec; 128(24):4285-4295. PubMed ID: 36281718
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
Wong SM; Ajjamada L; Weiss AC; Prakash I; Skamene S; Boileau JF; Pollak MN; Basik M
Cancer; 2022 Apr; 128(7):1365-1372. PubMed ID: 34919263
[TBL] [Abstract][Full Text] [Related]
3. Risk of male breast cancer after Hodgkin lymphoma.
de Vries S; Krul IM; Schaapveld M; Janus CPM; Rademakers SE; Roesink JM; Nijziel MR; Bilgin YM; Aleman BMP; van Leeuwen FE
Blood; 2023 Aug; 142(9):806-811. PubMed ID: 37390297
[TBL] [Abstract][Full Text] [Related]
4. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.
Travis LB; Hill D; Dores GM; Gospodarowicz M; van Leeuwen FE; Holowaty E; Glimelius B; Andersson M; Pukkala E; Lynch CF; Pee D; Smith SA; Van't Veer MB; Joensuu T; Storm H; Stovall M; Boice JD; Gilbert E; Gail MH
J Natl Cancer Inst; 2005 Oct; 97(19):1428-37. PubMed ID: 16204692
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.
Krul IM; Opstal-van Winden AWJ; Aleman BMP; Janus CPM; van Eggermond AM; De Bruin ML; Hauptmann M; Krol ADG; Schaapveld M; Broeks A; Kooijman KR; Fase S; Lybeert ML; Zijlstra JM; van der Maazen RWM; Kesminiene A; Diallo I; de Vathaire F; Russell NS; van Leeuwen FE
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):843-853. PubMed ID: 28888722
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
De Bruin ML; Sparidans J; van't Veer MB; Noordijk EM; Louwman MW; Zijlstra JM; van den Berg H; Russell NS; Broeks A; Baaijens MH; Aleman BM; van Leeuwen FE
J Clin Oncol; 2009 Sep; 27(26):4239-46. PubMed ID: 19667275
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy-Related Dose and Irradiated Volume Effects on Breast Cancer Risk Among Hodgkin Lymphoma Survivors.
Roberti S; van Leeuwen FE; Ronckers CM; Krul IM; de Vathaire F; Veres C; Diallo I; Janus CPM; Aleman BMP; Russell NS; Hauptmann M
J Natl Cancer Inst; 2022 Sep; 114(9):1270-1278. PubMed ID: 35771630
[TBL] [Abstract][Full Text] [Related]
8. A pilot study evaluating chemotherapy tolerability for breast cancer patients who have received prior treatment and chest radiation for Hodgkin Lymphoma.
Watson AP; Peterson B; Lee C; Baxstrom K; Turcotte L; Vogel R; Blaes A
Cancer Treat Res Commun; 2018; 15():1-6. PubMed ID: 30207281
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM; Geurts YM; Aleman BMP; Lugtenburg PJ; Rademakers SE; de Weijer RJ; Schippers MGA; Ta BDP; Plattel WJ; Zijlstra JM; van der Maazen RWM; Nijziel MR; Ong F; Schimmel EC; Posthuma EFM; Kersten MJ; Böhmer LH; Muller K; Koene HR; Te Boome LCJ; Bilgin YM; de Jongh E; Janus CPM; van Leeuwen FE; Schaapveld M
J Clin Oncol; 2024 Feb; ():JCO2301386. PubMed ID: 38359378
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
van Nimwegen FA; Schaapveld M; Janus CP; Krol AD; Petersen EJ; Raemaekers JM; Kok WE; Aleman BM; van Leeuwen FE
JAMA Intern Med; 2015 Jun; 175(6):1007-17. PubMed ID: 25915855
[TBL] [Abstract][Full Text] [Related]
11. Management of breast cancer after Hodgkin's lymphoma and paediatric cancer.
Terenziani M; Massimino M; Magazzù D; Gandola L; Capri G; Carcangiu ML; Catania S; Di Russo A; Gennaro M; Meazza C; Podda M; Schiavello E; Valagussa P
Eur J Cancer; 2015 Sep; 51(13):1667-74. PubMed ID: 26092639
[TBL] [Abstract][Full Text] [Related]
12. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy.
Dores GM; Anderson WF; Beane Freeman LE; Fraumeni JF; Curtis RE
Br J Cancer; 2010 Sep; 103(7):1081-4. PubMed ID: 20842115
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population.
Boerman LM; Berendsen AJ; van der Meer P; Maduro JH; Berger MY; de Bock GH
Support Care Cancer; 2014 Jul; 22(7):1949-58. PubMed ID: 24584711
[TBL] [Abstract][Full Text] [Related]
14. Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphoma.
Veit-Rubin N; Rapiti E; Usel M; Benhamou S; Vinh-Hung V; Vlastos G; Bouchardy C
Oncologist; 2012; 17(6):783-91. PubMed ID: 22588325
[TBL] [Abstract][Full Text] [Related]
15. Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.
Horst KC; Hancock SL; Ognibene G; Chen C; Advani RH; Rosenberg SA; Donaldson SS; Hoppe RT
Ann Oncol; 2014 Apr; 25(4):848-851. PubMed ID: 24608191
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of breast cancer occurring after treatment for Hodgkin's lymphoma: case-control analysis.
Alm El-Din MA; Hughes KS; Raad RA; Goldberg SI; Aisenberg AC; Niemierko A; Taghian AG
Radiat Oncol; 2009 Jun; 4():19. PubMed ID: 19566943
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.
Elkin EB; Klem ML; Gonzales AM; Ishill NM; Hodgson D; Ng AK; Marks LB; Weidhaas J; Freedman GM; Miller RC; Constine LS; Myrehaug S; Yahalom J
J Clin Oncol; 2011 Jun; 29(18):2466-73. PubMed ID: 21576642
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.
van Leeuwen FE; Ng AK
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):323-330. PubMed ID: 27913498
[TBL] [Abstract][Full Text] [Related]
19. Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
Sud A; Thomsen H; Sundquist K; Houlston RS; Hemminki K
J Clin Oncol; 2017 May; 35(14):1584-1590. PubMed ID: 28384078
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
de Vries S; Schaapveld M; Janus CPM; Daniëls LA; Petersen EJ; van der Maazen RWM; Zijlstra JM; Beijert M; Nijziel MR; Verschueren KMS; Kremer LCM; van Eggermond AM; Lugtenburg PJ; Krol ADG; Roesink JM; Plattel WJ; van Spronsen DJ; van Imhoff GW; de Boer JP; Aleman BMP; van Leeuwen FE
J Natl Cancer Inst; 2021 Jun; 113(6):760-769. PubMed ID: 33351090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
